A multinational consensus from three major European obesity and nutrition bodies — EASO, EFAD, and ECPO — synthesizes pragmatic clinical guidance for managing GLP-1 receptor agonists and dual GLP-1-GIP agonists (e.g., semaglutide, tirzepatide) across nutritional, functional, and psychological domains. Core recommendations emphasize adequate protein intake and progressive resistance training to preserve fat-free mass during rapid weight loss, micronutrient monitoring to counter reduced dietary intake, and structured psychological screening to address shifts in food reward, coping behaviors, and social identity tied to eating.
The significance here extends well beyond clinical protocol. The GLP-1/GIP drug class is now prescribed to tens of millions globally, yet the field has operated without harmonized guidance on the non-pharmacological risks these agents create. Fat-free mass loss — potentially accounting for 25–40% of total weight lost in some studies — represents a genuine longevity liability, accelerating sarcopenia risk in adults already metabolically vulnerable. The explicit acknowledgment of identity disruption around food is unusually sophisticated for a pharmacotherapy consensus and reflects emerging evidence linking eating behavior to psychological self-concept. Limitations are real: this is a consensus statement, not a systematic meta-analysis, so recommendations carry expert-opinion weighting rather than high-certainty trial evidence. Longitudinal data on micronutrient depletion trajectories and post-cessation weight regain remain sparse. Still, for clinicians and health-aware adults navigating incretin therapy, this document is the most comprehensive safety framework yet published — practically paradigm-shifting for standard of care.
